Proceedings of the Tenth International Conference of Drug Regulatory Authorities (ICDRA) - Hong Kong, China, 24 - 27 June 2002
(2002; 166 pages) View the PDF document
Table of Contents
View the documentAbbreviations and acronyms used in this report
Open this folder and view contentsOpening ceremony
Open this folder and view contentsHerbal medicines
Open this folder and view contentsKeynote address
Open this folder and view contentsSafety of blood-derived products
Open this folder and view contentsAntimicrobial resistance - new initiatives
Open this folder and view contentsHarmonization I
Open this folder and view contentsHarmonization II
Open this folder and view contentsProtection of trial subjects in clinical trials
Open this folder and view contentsRegulating biotechnology products
Open this folder and view contentsRegulatory challenges: health sector reform and drug regulatory capacity
Open this folder and view contentsAccess to drugs and vaccines I
Open this folder and view contentsAccess to drugs and vaccines II
Open this folder and view contentsCounterfeit pharmaceutical products
Close this folderHomoeopathy
View the documentRegistration criteria for homoeopathic medicinal products in the United Arab Emirates
View the documentThe regulatory framework for homoeopathic medicinal products in Germany and in the European Union
View the documentRegulation of homoeopathic products in the United Kingdom
View the documentRecommendations
Open this folder and view contentsSafety monitoring
Open this folder and view contentsE-Commerce
Open this folder and view contentsCurrent topics
Open this folder and view contentsRegulatory challenges of new technologies
View the documentList of participants
View the documentBack cover
 

Recommendations

1. In collaboration with Member States, WHO should harmonize definitions of homoeopathic products and practices in order to allow classification and identification of homoeopathic products at national level.

2. WHO should cooperate with governmental institutions to establish recommendations for safe degrees of dilutions of homoeopathic preparations.

3. In collaboration with Member States, WHO should promote the exchange of information. A reference list of information resources on homoeopathic medicines, including official pharmacopoeias should be made available. WHO should develop systems to collect and provide information to consumers on the safe use of homoeopathic medicines.

4. WHO should provide guidance to governments and NGOs for training of homoeopathic medicine providers.

5. Progress should be reported back to the ICDRA.

 

to previous section
to next section
 
 
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: October 7, 2014